Older patients with acute myeloid leukemia deserve individualized treatment
DC de Leeuw, GJ Ossenkoppele… - Current oncology reports, 2022 - Springer
Abstract Purpose of Review Treatment of elderly patients with acute myeloid leukemia is a
known challenge for hematologists due to patient diversity, heterogeneous disease biology …
known challenge for hematologists due to patient diversity, heterogeneous disease biology …
Harnessing the benefits of available targeted therapies in acute myeloid leukaemia
H Kantarjian, NJ Short, C DiNardo, EM Stein… - The Lancet …, 2021 - thelancet.com
Research has resulted in regulatory approval of nine agents for acute myeloid leukaemia
indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor …
indications by the US Food and Drug Administration since 2017: the Bcl-2 inhibitor …
A randomized comparison of CPX-351 and FLAG-Ida in adverse karyotype AML and high-risk MDS: The UK NCRI AML19 trial
Liposomal daunorubicin and cytarabine (CPX-351) improved overall survival (OS)
compared with 7+ 3 chemotherapy in older patients with secondary acute myeloid leukemia …
compared with 7+ 3 chemotherapy in older patients with secondary acute myeloid leukemia …
Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia
Accurate classification and risk stratification are critical for clinical decision making in
patients with acute myeloid leukemia (AML). In the newly proposed World Health …
patients with acute myeloid leukemia (AML). In the newly proposed World Health …
Non-T-depleted haploidentical transplantation with post-transplant cyclophosphamide in patients with secondary versus de novo AML in first complete remission: a …
We compared outcomes of adult patients with secondary acute myeloid leukemia (sAML)
versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) …
versus de novo AML after non-T-depleted haploidentical stem cell transplant (HaploSCT) …
CPX-351 in higher risk myelodysplastic syndrome and chronic myelomonocytic leukaemia: a multicentre, single-arm, phase 2 study
P Peterlin, Y Le Bris, P Turlure, P Chevallier… - The Lancet …, 2023 - thelancet.com
Background CPX-351, an encapsulated form of cytarabine and daunorubicin, has shown
greater efficacy than the classic 3+ 7 treatment administration in secondary acute myeloid …
greater efficacy than the classic 3+ 7 treatment administration in secondary acute myeloid …
Understanding the continuum between high-risk myelodysplastic syndrome and acute myeloid leukemia
PD Zavras, I Sinanidis, P Tsakiroglou… - International journal of …, 2023 - mdpi.com
Myelodysplastic syndrome (MDS) is a clonal hematopoietic neoplasm characterized by
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …
bone marrow dysplasia, failure of hematopoiesis and variable risk of progression to acute …
Targeting and Monitoring Acute Myeloid Leukaemia with Nucleophosmin-1 (NPM1) Mutation
L Chin, CYG Wong, H Gill - International Journal of Molecular Sciences, 2023 - mdpi.com
Mutations in NPM1, also known as nucleophosmin-1, B23, NO38, or numatrin, are seen in
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …
approximately one-third of patients with acute myeloid leukaemia (AML). A plethora of …
Chimeric antigen receptor T cells in acute myeloid leukemia
K Cummins, S Gill - Hematology/Oncology Clinics, 2023 - hemonc.theclinics.com
Background Approximately 20,000 Americans are diagnosed with AML each year at a
median age of diagnosis of 69, and the 5-year survival is approximately 31.7%(https://seer …
median age of diagnosis of 69, and the 5-year survival is approximately 31.7%(https://seer …
10-day decitabine versus 3+ 7 chemotherapy followed by allografting in older patients with acute myeloid leukaemia: an open-label, randomised, controlled, phase 3 …
M Lübbert, PW Wijermans, M Kicinski… - The Lancet …, 2023 - thelancet.com
Background Many older patients with acute myeloid leukaemia die or cannot undergo
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …
allogeneic haematopoietic stem-cell transplantation (HSCT) due to toxicity caused by …